LSBCF (LakeShore Biopharma Co) Retained Earnings: $-332.10 Mil (As of Mar. 2025)


What is LakeShore Biopharma Co Retained Earnings?

LakeShore Biopharma Co LSBCF Retained Earnings is $-332.10 Mil as of Mar. 2025.

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. LakeShore Biopharma Co's retained earnings for the quarter that ended in Mar. 2025 was $-332.10 Mil.

LakeShore Biopharma Co's quarterly retained earnings declined from Mar. 2024 ($-320.42 Mil) to Sep. 2024 ($-323.20 Mil) and declined from Sep. 2024 ($-323.20 Mil) to Mar. 2025 ($-332.10 Mil).

LakeShore Biopharma Co's annual retained earnings declined from Mar. 2023 ($-271.96 Mil) to Mar. 2024 ($-320.42 Mil) and declined from Mar. 2024 ($-320.42 Mil) to Mar. 2025 ($-332.10 Mil).


LakeShore Biopharma Co  (OTCPK:LSBCF) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


LakeShore Biopharma Co Retained Earnings Historical Data

* Premium members only.

The historical data trend for LakeShore Biopharma Co's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

LakeShore Biopharma Co Retained Earnings Chart

LakeShore Biopharma Co Annual Data
Trend Mar21 Mar22 Mar23 Mar24 Mar25
Retained Earnings
-207.94 -250.70 -271.96 -320.42 -332.10

LakeShore Biopharma Co Semi-Annual Data
Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25
Retained Earnings Get a 7-Day Free Trial Premium Member Only -271.96 -280.71 -320.42 -323.20 -332.10

LakeShore Biopharma Co Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Frequently Asked Questions Learn more about Retained Earnings →
What does a Retained Earnings of $-332.10 Mil mean?
LakeShore Biopharma Co (LSBCF) has a Retained Earnings of $-332.10 Mil as of Mar. 2025. Retained earnings is the amount of net income not issued to shareholders. View historical data on LakeShore Biopharma Co and its competitors.
Is LakeShore Biopharma Co's Retained Earnings too high?
LakeShore Biopharma Co's current Retained Earnings is $-332.10 Mil.
How does LakeShore Biopharma Co's Retained Earnings compare to ACUT and PPCB?
LakeShore Biopharma Co's Retained Earnings of $-332.10 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Retained Earnings for a Biotechnology company?
A good Retained Earnings depends on the Biotechnology industry context. However, Retained Earnings should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Retained Earnings mean?
A high Retained Earnings can signal that a stock is expensive relative to its fundamentals. Retained earnings is the amount of net income not issued to shareholders. View historical data on LakeShore Biopharma Co and its competitors. LakeShore Biopharma Co's current Retained Earnings is $-332.10 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LakeShore Biopharma Co stock overvalued right now?
LakeShore Biopharma Co (LSBCF) has a current Retained Earnings of $-332.10 Mil. The current Retained Earnings is $-332.10 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Retained Earnings calculated?
Retained Earnings is calculated from a company's financial statements. For LakeShore Biopharma Co (LSBCF), the current Retained Earnings is $-332.10 Mil as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

LakeShore Biopharma Co Business Description

Address 38 Yongda Road, Building No. 2, Daxing Biomedical Industry Park, Daxing District, Beijing, CHN, 102629
LakeShore Biopharma Co Ltd is a biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, Shingles, and other virus infections. The company operates in China, the United States, Singapore, and the Philippines.